Article
Drug Shortage Resolved
Oxford Pharmaceutical's (Totowa, NJ) antidepressant drug “Marplan” (isocarboxazid, 10-mg dosage) has been removed from the US Food and Drug Administration’s list of drug shortages. Oxford resumed normal distribution of Marplan on May 27.
Marplan is a second-line treatment for depression offered as an option for patients who are unresponsive to other antidepressants such as selective serotonin reuptake inhibitors or traditional antidepressants such as amitriptyline.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.